Sistemic
is delighted to announce that its proprietary technology (SistemQC
TM)
has been chosen to form a key part of the research and production
process for a landmark multinational collaborative project led by
TiGenix, Belgium and including partners from Spain, France, the
Netherlands as well as the UK and Belgium. The project, REGENER-AR, will
bring the first stem cell therapy product for rheumatoid arthritis,
Cx611, through final research and clinical development.
The
proprietary SistemQC
TM miRNA-based stem cell characterization and
quality control tool-kit will provide important insights into process
optimization and QC testing of TiGenix's pioneering cell therapy
product. This work is part of a larger collaborative effort led by
TiGenix and funded by a EUR 5.9 million European Seventh Framework
Programme (FP7) grant under the topic "Regenerative medicine clinical
trials" within the Health theme.
SistemQC
TM
combines robust miRNA profiling with superior statistical analytics and
multi-layered contextual analysis to generate a fingerprint of key
miRNAs (kmiR
TMs). This approach provides a succinct read out on the
status of the cells, with the added benefit of being able to interpret
the underlying biological effects associated with any change observed.
Additionally, the kmiR
TM fingerprints can be adapted to a QPCR method for
ease of integration into laboratory routine, and provide rapid testing.
They can be used as a cell phenotype characterization tool in
combination with a qualitative assessment of product cell composition,
or to monitor product quality during scale-up and aid the selection of
manufacturing process improvements.
Dr
Vincent O'Brien, Sistemic's Chief Science Officer said, "We are
honoured to be working with TiGenix and Cellerix, its Spanish subsidiary
as well as partners from all over Europe. Sistemic will provide
in-depth product characterization data during the clinical trial with
Cx611. This will be a critical part of the development and subsequent
production process. We look forward to collaborating with all of the
consortium members on this important project as we are supportive of the
potential of cell therapy products to bring real benefits to those
patients suffering from rheumatoid arthritis."
The
collaborative project, referred to as the REGENER-AR consortium, brings
together 10 top-level research institutes, medical entities and
biotechnology companies from Spain, France, the UK, the Netherlands and
Belgium. The consortium has defined a clinical translational project
with the aim of developing a broadly available, clinically applicable
treatment for rheumatoid arthritis by exploiting human allogeneic
mesenchymal adult stem cells extracted from adipose tissue (eASCs).
Sistemic
provides innovative miRNA-based products to the cell therapy, drug
development and bioprocessing markets. The company's pioneering approach
enables companies to accelerate drug discovery and development
programmes whilst reducing development risk.
For further information
visit:
www.sistemic.co.uk
Subscribe to any of our newsletters for the latest on new laboratory products, industry news, case studies and much more!
Request your free copies HERE
Popular this Month
Top 10 most popular articles this month
Today's Picks
Looking for a Supplier?
Search by company or by product
Please note Lab Bulletin does not sell, supply any of the products featured on this website. If you have an enquiry, please use the contact form below the article or company profile and we will send your request to the supplier so that they can contact you directly.
Lab Bulletin is published by newleaf marketing communications ltd.